|Bid||22.44 x 800|
|Ask||22.45 x 900|
|Day's Range||21.54 - 22.73|
|52 Week Range||7.57 - 23.48|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2023 - Feb 27, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||51.77|
Subscribe to Yahoo Finance Plus to view Fair Value for RCKT
In this article, we will take a look at the 12 cash-rich small cap stocks to invest in. To see more such companies, go directly to 5 Cash-Rich Small Cap Stocks To Invest In. In 2022, standard diversified portfolios suffered through their worst-performing year in a century. Despite the decline in markets this past year, […]
Rocket Pharmaceuticals (RCKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.